SCHEMBL2904975

SCHEMBL2904975

CC(C)(C)c1cc2cccc([N+](=O)[O-])c2o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.56
ALDH1A1 P00352 1/20 0.42
TDP1 Q9NUW8 3/20 0.42
PDE10A Q9Y233 1/20 0.41
CHRNA7 P36544 1/20 0.40
GPR35 Q9HC97 3/20 0.40
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
CSNK2A3 Q8NEV1 1/20 0.38
NOS1 P29475 2/20 0.38
NOS2 P35228 2/20 0.38
S100A4 P26447 1/20 0.38
HSD17B10 Q99714 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7828455 0.79 MAOA (0.60) MAOAALDH1A1TDP1PDE10ACHRNA7
SCHEMBL28301342 0.76 MAOA (0.60) MAOAALDH1A1TDP1PDE10ACHRNA7
SCHEMBL28188822 0.76 MAOA (0.60) MAOAALDH1A1TDP1PDE10ACHRNA7
SCHEMBL27921417 0.76 MAOA (0.60) MAOAALDH1A1TDP1PDE10ACHRNA7
SCHEMBL15828669 0.75 MEN1 (0.60) ALDH1A1TDP1GPR35MEN1MAPT
SCHEMBL11540656 0.73 MAOA (0.57) MAOAALDH1A1TDP1PDE10ACHRNA7
SCHEMBL25094249 0.73 MAOA (0.47) MAOAALDH1A1TDP1TSHR
SCHEMBL12755277 0.73 MAOB (0.51) MAOAMEN1KMT2A
SCHEMBL8294084 0.72 CYP2D6 (0.49) MAOAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL2897463 0.72 GPR35 (0.68) MAOAALDH1A1TDP1PDE10ACHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825253-B2 2-aminoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
EP-2076495-B1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES HOFFMANN LA ROCHE (CH) 2010-08-18 EP disclosed
EP-2076495-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F.HOFFMANN-LA ROCHE AG (CH) 2009-07-08 EP disclosed
WO-2008037626-A1 QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-03 WO disclosed
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081907-A1 2-AMINOQUINOLINE DERIVATIVES AR, ADRA2C, RCC2 MAOA 1728/4885ALDH1A1 872/4885TDP1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.